Series Description
The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.

Session Description
Minorities and women are particularly vulnerable to Alzheimer’s disease (AD). Former Alzheimer’s Association President and CEO Harry Johns noted that relative to Caucasians “the threat [of AD] is even more substantial in the African-American and Hispanic communities.” This is partially related to the higher incidence of dementia and AD as well as increased severity of symptoms in African Americans. That increased incidence or risk remains high, despite adjustments for education, family dementia histories, and hypertension co-morbidity. Socioeconomic status, other health conditions, health care access, and delays in physician consultation likely contribute to--but do not explain--all those disparities.

Increased research into African Americans and other minority populations with AD is crucial to the goals of precision medicine and yet this is traditionally an understudied population. This does, however, appear to be changing. Studies indicate the advantage of using different approaches to understanding what is likely to be a complex picture of AD-related ethnicity differences.

Women have a higher incidence of AD at later ages. For example, among people who are 71 years of age or older, 16% of women have AD compared with only 11% of men. Better understanding of sex differences involved in the cause and progression of AD could contribute to better drugs and other types of interventions to slow the disease progression.

This presentation will discuss research into protein levels in post-mortem African American and Caucasian brain tissue from both genders to explore ethnicity- and gender-related differences. The selected proteins include those thought to be critically involved in AD. Those proteins were examined in samples of the middle temporal gyrus that were matched for age at death since this region is critically involved in language processing and generation and has been shown to be significantly affected by AD.

Session References
Series Objectives
1. Discuss the research conducted at the FDA.
2. Explain how FDA science impacts public health.

Session Learning Objectives
After completion of this activity, the participant will be able to:
1. Explain the neurodegenerative protein differences between African Americans and Caucasians of both genders
2. Describe how those protein differences might contribute to the differences in disease severity
3. Discuss the advantages of multiplex technology
4. Explain the importance of this field of research for Alzheimer’s disease as well as others.

Target Audience
This activity is intended for physicians, pharmacists, nurses and other scientists within the agency and external community.

About the Presenters
Sherry Ferguson, PhD, is a Research Psychologist in the Division of Neurotoxicology at FDA’s National Center for Toxilogical Research, where she has worked since 1990. For more than 25 years, she has been involved in neurotoxicological research. Dr. Ferguson received her PhD in Physiological Psychology from the University of Wisconsin at Madison. She is on the editorial board of several scientific journals and is a past president of the Developmental Neurotoxicology Society (formerly, the Neurobehavioral Teratology Society). She holds adjunct status at the University of Arkansas for Medical Sciences and the University of Arkansas at Little Rock.

Since 2009, Vijayalakshmi (Viji) Varma, PhD, has worked as a research biologist in the Division of Systems Biology in FDA’s National Center for Toxicological Research. She received her PhD in Biochemistry and Cell Biology from Manipal Academy of Higher Education, Manipal University, India. For over 13 years, she has been involved in research exploring metabolic syndrome and its comorbidities including obesity, insulin resistance, and obesity-induced inflammation, in clinical translational studies and in disease modeling, using in vitro cell culture and in vivo rodent systems. She is currently leading research efforts to explore the impact of obesity on drug-induced toxicities.

Schedule

<table>
<thead>
<tr>
<th>Date/Time/Place</th>
<th>Lecture Title</th>
<th>Lecturers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, January 11</td>
<td>FDA Grand Rounds: Ethnicity- and Gender-related Differences in Alzheimer’s Disease</td>
<td>Sherry Ferguson, PhD and Vijayalakshmi (Viji) Varma, PhD</td>
</tr>
<tr>
<td>12:00 PM-1:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDA White Oak CSU 2031</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Remote Access Instructions
Webscast Registration: To register for the webcast, please click the link below and then follow the instructions on the registration page. After you register you will receive a link via email to access the live webinar. You must log in with your username and password which you create when you register. Please pre-register at least one day before the event to ensure you receive the access link email and outlook invitation for the session.

https://collaboration.fda.gov/grandroundsjan1118/event/registration.html

For technical assistance please contact Jeffery Rexrode at Jeffery.Rexrode@fda.hhs.gov.
HHS/LMS Registration Link
https://lms.learning.hhs.gov/Saba/Web/Main/goto/RegisterCatalog?offeringId=class000000000130811&oneClickLearningON=true

Requirements to Receive Credit for Each Lecture/Session
Participants must create an account to attest their attendance and complete the final activity evaluation via the CE Portal (www.ceportal.fda.gov). The training point of contact will email the evaluation to participants within 24 hours after each session. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Reasonable Accommodations
The FDA provides reasonable accommodations for all individuals with disabilities who apply for training or developmental opportunities. If you need a reasonable accommodation for any part of the training application process, please notify the training contact for this particular event. Reasonable accommodation requests are granted on a case-by case basis. Should you need sign language interpretation to attend this event, please send the request to Interpreting.Services@oc.fda.gov.